Small Cell Lung Cancer

During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.

IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.

With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.

Biomarker testing should be done on all patients with an initial diagnosis of advanced nonsquamous non–small cell lung cancer, but the testing rates in the real world are lower than they should be, particularly for underserved or minority populations, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

A study carried out at 4 health care systems found rates of stage I lung cancer increased, and rates of stage IV cancer decreased, once screening was initiated.

Hatim Husain, MD, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer.

An updated national coverage determination from CMS about lung cancer screening has some stakeholders concerned that the quality of decision-making tools used by providers and patients may weaken.

Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.

A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.

Edward Arrowsmith, MD, concludes with his thoughts on developing therapies and how they are implemented into clinical pathways for NSCLC treatment.

Dr Arrowsmith discusses the role immune checkpoint inhibitors play in NSCLC therapy, both as monotherapy and in combination therapy.

Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval in non–small cell lung cancer (NSCLC), said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

Health care providers can help alleviate caregiver burdens by teaching coping strategies, the authors said.

Patients were more likely to accept intervention from a psychologist if they received regular questionnaires.

An oncology expert explains how clinical and non-clinical evidence impact the clinical pathway decision-making for patients with NSCLC.

Edward Arrowsmith, MD, describes the value of using clinical pathways in NSCLC therapy and how they are used at his institution, including their multiple sites of care.

New real-world evidence on non–small cell lung cancer (NSCLC) aligns with the results of a 2017 clinical trial.

More people are eligible for screening, but a new analysis suggests lung cancer disparities are due to more than eligibility status.

The research may eventually help clinicians optimize therapy with immune checkpoint inhibitors.

Two studies showed how hospital-based trigger systems could help guide patients toward appropriate goals of care and in some cases palliative care.

Our experts conclude with their final thoughts on the future of NSCLC treatment.

Three medical professionals recommend educational needs for both payers and providers within the NSCLC treatment landscape.

Drs Sabari and Spira comment on the use KRAS inhibitors in both frontline and combination therapies.

A new review notes advances and remaining questions, and calls for better incorporation of data from veterans.

The panel concludes by offering key takeaways for viewers and listeners on ILD therapy.

The panel participants relay unmet needs they have found when treating ILD, and discuss promising therapy developments that could improve the treatment landscape.

Better screenings and improved therapies have helped boost non–small cell lung cancer (NSCLC) outcomes, but investigators said some patient groups have seen less improvement than others.

Dr Dietrich discusses patients acquiring and providers managing resistance to KRAS inhibition.